Trial Profile
Randomized Study of ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Patients Aged From 18 to 59 Years With Diffuse Large B-cell Lymphoma and a Age-adjusted IPI of 1.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Rituximab (Primary) ; Bleomycin; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine; Vindesine
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- 03 Mar 2011 Additional lead trial centre and investigators identified as reported by ClinicalTrials.gov.
- 27 Jan 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 27 Jan 2009 Actual end date (Jan 2009) added as reported by ClinicalTrials.gov.